Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.90% $14.55
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 876.48 mill |
EPS: | -2.75 |
P/E: | -5.29 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 60.24 mill |
Avg Daily Volume: | 0.418 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.29 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.90x |
Company: PE -5.29 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.837 (-94.25%) $-13.71 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 13.52 - 15.58 ( +/- 7.07%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-23 | Lefebvre Eric | Buy | 42 900 | Common Stock |
2024-01-23 | Lefebvre Eric | Buy | 85 800 | Stock Option (Right to Buy) |
2024-01-23 | Hull Hans | Buy | 31 500 | Common Stock |
2024-01-23 | Hull Hans | Buy | 63 000 | Stock Option (Right to Buy) |
2024-01-23 | Ouimette Mike | Buy | 31 500 | Common Stock |
INSIDER POWER |
---|
66.92 |
Last 98 transactions |
Buy: 2 502 892 | Sell: 552 083 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $14.55 (2.90% ) |
Volume | 0.244 mill |
Avg. Vol. | 0.418 mill |
% of Avg. Vol | 58.34 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $16.20 | N/A | Active |
---|
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Date | Signal | @ |
---|---|---|
YAR.OL | Mar 27 - 08:05 | NOK342.90 |
TGS.OL | Mar 27 - 08:05 | NOK118.20 |
AGLX.OL | Mar 27 - 08:05 | NOK30.95 |
GOGL.OL | Mar 27 - 08:09 | NOK136.70 |
EQNR.OL | Mar 27 - 08:08 | NOK286.40 |
MULTI.OL | Mar 27 - 08:05 | NOK148.00 |
DNB.OL | Mar 27 - 08:05 | NOK215.10 |
MOWI.OL | Mar 27 - 08:08 | NOK198.95 |
CADLR.OL | Mar 27 - 08:05 | NOK53.10 |
CLUSD | Mar 28 - 04:46 | $81.67 |